A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
about
Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectivesRecent Progress in the Prevention of Serogroup B Meningococcal Disease.Meningococcal B vaccination: real-world experience and future perspectives.Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH bindingClonal analysis of meningococci during a 26 year period prior to the introduction of meningococcal serogroup C vaccines.Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity.Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.Type VI secretion system sheaths as nanoparticles for antigen display.Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in CombinationVaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?Evaluation of a protective effect of in ovo delivered Campylobacter jejuni OMVs.Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.Concurrent meningococcal and herpes simplex infection in a non-immunocompromised child.Evolving meningococcal immunization strategies.The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.Will booster doses be required for serogroup B meningococcal vaccine?Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes.
P2860
Q26770702-C28F9F5C-DE0A-452D-8D95-E6ED0F29211DQ30235040-6778EADB-50C0-4342-BE93-959FD4E31F48Q30249575-A74F23EB-3566-4CA4-834F-14ED19256C6AQ33417375-C561499E-1010-403A-9726-5F3F512D5D5EQ33703560-EAC07F53-4EC1-479F-9157-C6629020C1DDQ34237895-661ED333-A09C-4B0F-9E4B-3D46F4710493Q35006862-10AA1167-6026-4507-90A3-CDB1DFB00190Q35033443-D540446C-5408-4B4C-83FC-79C076D00E57Q35463235-A159D3EA-43EE-4624-B342-4724DD501983Q36710694-2553FACB-6FD5-4A39-9C6E-0D11BBD35BA7Q36764403-C4569EFB-8460-4FA5-9275-C01A61776FDFQ37130205-6665C0AC-32FB-4F78-A2F3-6F8B948DC4E1Q37280943-C76F3D3E-EF28-487E-ACF6-F028102E6759Q37309237-2783D345-949E-40DD-8D5E-D40625E6B962Q37711735-EA0F7FED-E35F-4111-B630-228D8CAD2B45Q38286082-9F8BDB7D-97C8-4F5E-9612-C70818BFE40CQ38599522-F03FE038-4E05-47AB-872E-3A3E81BF22D1Q40408137-CE2A6CB0-A4ED-4C52-B4DB-F1D4AA6B4AC4Q44496407-A524A81E-C814-4FA8-AF5B-647991316EC2Q52682421-51D4D317-657A-4BEB-B430-28A2A872E5DD
P2860
A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A multicomponent serogroup B m ...... and what are we yet to learn?
@en
type
label
A multicomponent serogroup B m ...... and what are we yet to learn?
@en
prefLabel
A multicomponent serogroup B m ...... and what are we yet to learn?
@en
P2860
P1476
A multicomponent serogroup B m ...... and what are we yet to learn?
@en
P2093
Natalie G Martin
P2860
P304
P356
10.1586/14760584.2013.814862
P577
2013-08-01T00:00:00Z